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Years before insulin was discovered, anti-inflammatory sodium salicylate was used to treat diabetes in 1901. Intriguingly for many 
years that followed, diabetes was viewed as a disorder of glucose metabolism, and then it was described as a disease of dysregu-
lated lipid metabolism. The diabetes research focused on the causal relationship between obesity and insulin resistance, a major 
characteristic of type 2 diabetes. It is only within the past 20 years when the notion of inflammation as a cause of insulin resistance 
began to surface. In obesity, inflammation develops when macrophages infiltrate adipose tissue and stimulate adipocyte secretion 
of inflammatory cytokines, that in turn affect energy balance, glucose and lipid metabolism, leading to insulin resistance. This re-
port reviews recent discoveries of stress kinase signaling involving molecular scaffolds and endoplasmic reticulum chaperones 
that regulate energy balance and glucose homeostasis. As we advance from a conceptual understanding to molecular discoveries, 
a century-old story of inflammation and insulin resistance is re-born with new ideas.
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INTRODUCTION
Insulin resistance is a major characteristic of type 2 diabetes, 
which affects more than 250 million people worldwide [1]. 
Since insulin resistance is as an early and requisite event in the 
development of type 2 diabetes, understanding the cause of 
insulin resistance and identifying therapeutic intervention to 
treat insulin resistance have a global significance [2]. It is well 
established that obesity is a major cause of insulin resistance, 
and weight loss is known to improve insulin sensitivity in diabet-
ic subjects [3]. However, the underlying mechanism by which 
obesity causes insulin resistance remains unclear. A number of 
interesting hypotheses and pathways have recently emerged 
that individually or collectively can explain the important link 
between obesity and insulin resistance [4,5].
  One of the most exciting topics in recent diabetes research 
is the role of inflammation in type 2 diabetes. In 1993, Hotamis-
ligil et al. [6] reported the role of adipose expression tumor 
necrosis factor-a (TNF-a) in obesity-linked insulin resistance. 
This was immediately followed by a landmark discovery of 
obese (ob) gene by Zhang et al. in 1994 that led to a frantic search 
and identification of a host of adipocyte-derived hormones, 
such as leptin and adiponectin, that potently regulate glucose 
homeostasis [7,8]. The birth of “adipocentric” view of diabetes 
has taken place. Despite the early discovery of TNF-a as a 
novel inflammatory cytokine to regulate glucose metabolism, 
the role of inflammation in diabetes was not established until 
a series of clinical observations that supported laboratory 
findings. In 1997, Pickup et al. [9] reported a significant asso-
ciation between interleukin-6 (IL-6) and type 2 diabetes. This 
was further supported by Kern et al. [10] who described a role 
of adipose-derived TNF-a and IL-6 in human obesity and in-
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sulin resistance.
  At present, there is little doubt that adipose tissue is a mas-
ter regulator of inflammation, and inflammation mediates in-
sulin resistance in obesity [11]. Interestingly, this notion is not 
new, and a careful review of historical studies finds that Wil-
liamson [12] reported the beneficial effects of anti-inflamma-
tory sodium salicylate on the treatment of diabetes in 1901. 
This review will describe recent discoveries on the underlying 
mechanism by which inflammation causes insulin resistance 
and therefore attempt to advance our understanding on a cen-
tury-old notion.
JNK1 REGULATES ADIPOSE 
INFLAMMATION IN OBESITY
The c-Jun NH2-terminal kinase 1 (JNK1) signaling pathway is 
involved in the pathogenesis of obesity, insulin resistance, and 
type 2 diabetes [13]. In obese state induced by chronic high-fat 
diet (HFD) or genetic manipulation, JNK1 is activated and me-
diates downstream signaling events that target glucose metabo-
lism [14]. JNK1 has been shown to promote a serine phospho-
rylation of insulin receptor substrate 1 (IRS-1), and this event 
inhibits insulin signaling transduction that leads to insulin re-
sistance [15]. Consistent with this, JNK1
-/- mice are protected 
from diet-induced insulin resistance, supporting the negative 
regulatory role of JNK1 on glucose metabolism [14]. However, 
this interpretation is not without arguments. Hirosumi et al. 
[14] observed that JNK1
-/- mice are also resistant to diet-in-
duced obesity. This is an important observation since the pro-
tective effects of JNK1 deficiency against diet-induced insulin 
resistance can be at least partially explained by the fact that 
JNK1
-/- mice became less obese after HFD. In fact, many trans-
genic mouse models that are resistant to diet-induced obesity 
remain more insulin sensitive following HFD due to their lean 
phenotypes [16,17]. Therapeutic intervention that reduces 
obesity in HFD-fed mice also results in improved insulin sen-
sitivity [18]. Using various genetic approaches, Roger Davis 
and his colleagues have extensively investigated the role of 
JNK1 in the context of insulin resistance in different metabolic 
organs. Their findings are anything but expected, and provide 
major advancement in our understanding of the role of JNK1 
in inflammation and insulin resistance.
  Adipose tissue is characterized by macrophage infiltration 
and increased cytokine secretion in obesity [19]. Adipose func-
tion of JNK1 was examined in mice with adipocyte-selective 
deletion of JNK1, which were generated using mice with con-
ditional (floxed) JNK1 and adipose-specific expression of Cre 
recombinase (Fabp4-Cre) [20]. In these mice, JNK1 was selec-
tively deleted in white and brown adipose tissue, while JNK1 
expression was preserved in other organs [20]. Following HFD, 
adipose JNK1 deficient mice became obese and gained similar 
fat mass as compared to Cre-expressing wild-type mice. De-
spite becoming obese, adipose JNK1 deficient mice were more 
insulin sensitive, based on insulin tolerance test, after HFD 
[20]. Surprisingly, improved insulin sensitivity was largely due 
to increased insulin action in liver as shown during the hyper-
insulinemic-euglycemic clamp in HFD-fed JNK1 deficient 
mice [20]. Insulin-stimulated Akt phosphorylation, which is 
normally reduced in HFD-fed wild-type liver, was increased 
in JNK1 deficient mice. The mechanism by which adipose de-
letion of JNK1 protects liver against diet-induced insulin resis-
tance involves adipocyte secretion of IL-6. High-fat feeding 
markedly elevates IL-6 mRNA and its circulating levels in obese, 
wild-type mice. However, JNK1 deletion in adipose tissue com-
pletely prevented diet-induced adipose secretion of IL-6, and 
maintained normal insulin action in liver. Thus, these findings 
indicate that adipose-derived IL-6 is an important mediator of 
diet-induced insulin resistance in liver, and that JNK1 is an 
important regulator of this cross-talk between adipose tissue 
and liver in obesity [20].
PROTECTIVE ROLE OF JNK1 IN HEPATIC 
STEATOSIS AND INSULIN RESISTANCE
The liver is a major organ of glucose homeostasis. In fasting 
state, liver produces glucose (hepatic glucose production) by 
breaking down stored glycogen and synthesizing new glucose 
from non-carbohydrate source to maintain euglycemia [21]. 
Following meals, hepatic glucose production is suppressed by 
insulin that involves insulin signaling pathway [22]. Insulin 
resistance and excess production of glucose by liver are the 
primary cause of fasting hyperglycemia in type 2 diabetes [23]. 
Recent studies using adenoviral delivery of dominant-negative 
JNK or JNK-shRNA have shown that JNK1 is an important 
regulator of hepatic glucose metabolism [24,25]. In a recent 
study of Sabio et al. [26], JNK1 was selectively deleted in hepa-
tocytes using albumin-cre as a promoter, and their findings are 
again remarkable. A high-fat feeding increased JNK1 activa-
tion in wild-type liver, but did not alter JNK1 activity in liver-
specific JNK1 deficient mice. In contrast to previously shown 139
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negative regulatory role of JNK1 on hepatic insulin signaling 
using adenovirus approach, cre-lox mediated JNK1 deletion 
in hepatocytes failed to rescue diet-induced insulin resistance 
in liver [26]. Instead, JNK1 deficient mice developed insulin 
resistance and hepatic steatosis on chow-fed state [26]. The 
hyperinsulinemic-euglycemic clamp showed that this was due 
to reduced hepatic insulin action and blunted Akt-mediated 
insulin signaling in liver-specific JNK1 deficient mice. JNK1 
deficiency in liver also elevated hepatic expression of genes as-
sociated with lipid metabolism (e.g., PGC-1b, PPARg, FAS, 
acetyl CoA carboxylase [ACC]) that resulted in hepatic steato-
sis in these mice [26]. Since non-alcoholic fatty liver disease is 
a major cause of liver dysfunction and is closely associated with 
metabolic syndrome [27], this newly identified role of JNK1 in 
regulating lipid metabolism is critical in understanding a major 
liver disease. Furthermore, insulin clearance by the liver is an 
important determinant of circulating insulin levels, and abnor-
mal hepatic clearance of insulin has been shown to modulate 
peripheral glucose metabolism and obesity [28,29]. In that re-
gard, hepatic JNK1 deficiency resulted in elevated insulin 
clearance that was compensated by increased insulin secretion 
[26]. Taken together, these findings indicate an intricate role of 
JNK1 in the regulation hepatic glucose and lipid metabolism.
JNK1 MEDIATES DIET-INDUCED INSULIN 
RESISTANCE IN SKELETAL MUSCLE
Skeletal muscle is a major organ of glucose disposal, and insu-
lin resistance in skeletal muscle is a hallmark feature of type 2 
diabetes [1]. Skeletal muscle deletion of insulin receptor or glu-
cose transporter (GLUT4) results in insulin resistance [30,31]. 
In addition to adipose tissue, high-fat feeding was recently 
shown to increase macrophage infiltration and cause inflam-
mation in skeletal muscle [32]. Obesity-induced macrophage 
infiltration in muscle was associated with increased local ex-
pression of IL-6 and TNF-a [32]. In that regard, both IL-6 and 
TNF-a are shown to alter insulin signaling and glucose me-
tabolism in skeletal muscle [33,34]. IL-6 was shown to activate 
STAT3-SOCS3 expression and promote SOCS3-mediated 
downregulation of insulin signaling in isolated hepatocytes 
and adipocytes [35,36]. TNF-a was shown to inhibit AMP-ac-
tivated protein kinase (AMPK) and alter glucose metabolism 
in skeletal muscle [34]. The role of JNK1 in muscle metabo-
lism was determined in muscle-specific JNK1 deficient mice 
using muscle creatine kinase (MCK-Cre) promoter [37]. A 
high-fat feeding caused JNK1 activation in skeletal muscle that 
was associated with insulin resistance in wild-type mice [37]. 
In contrast, diet-induced JNK1 activation was not detected in 
skeletal muscle of JNK1 deficient mice. Despite becoming 
obese, muscle-JNK1 deficient mice were protected from insu-
lin resistance and showed increased Akt activation and glucose 
metabolism in skeletal muscle following HFD [37]. Interest-
ingly, muscle JNK1 deletion resulted in increases in circulating 
levels of triglyceride and hepatic steatosis following HFD [37]. 
Muscle JNK1 deficiency also enhanced diet-induced inflam-
mation in adipose tissue, which was responsible for blunted 
Akt activation in adipose tissue and liver after HFD. Therefore, 
these findings implicate that JNK1 mediates diet-induced in-
sulin resistance in skeletal muscle, and further modulates lipid 
metabolism that secondarily affects adipose tissue inflamma-
tion and hepatic steatosis. This unexpected combination of 
events in response to muscle JNK1 deficiency again reflects a 
complex regulation of glucose and lipid metabolism by JNK1.
NERVOUS SYSTEM JNK1 REGULATES 
ENERGY BALANCE VIA HYPOTHALAMIC-
PITUITARY-THYROID AXIS
Of those recently identified cell-autonomous effects of JNK1, 
none is as intriguing and important as the role of JNK1 in the 
murine nervous system. Mice with whole body deletion of 
JNK1 are resistant to diet-induced obesity, suggesting a poten-
tial role of JNK1 in energy balance [14]. Since JNK1 deletion 
in adipose tissue, liver, and skeletal muscle did not affect diet-
induced weight gain, a different organ must therefore account 
for JNK1 regulation of diet-induced obesity. With established 
functions of hypothalamus and pituitary gland in regulating 
energy balance [38], brain is an obvious target of JNK1 effects 
on weight gain following HFD. This precise and logical ques-
tion was addressed in mice with brain-specific deletion of JNK1 
using Nestin-cre promoter [39]. Remarkably, JNK1 deficiency 
selectively in nervous system exactly recapitulated resistance 
to diet-induced obesity phenotypes observed in global JNK1-
deficient mice [14]. Following HFD, mice with nervous system 
JNK1 deficiency remained lean as compared to wild-type lit-
termates. Their positive energy balance was due to reduced 
food intake, and increased whole body energy expenditure in 
JNK1 deficient mice [39]. As a result of their leanness, nervous 
system JNK1 deficient mice were more insulin sensitive than 
wild-type mice after HFD [39]. Interestingly, gene expression 140
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analysis showed increased expression of mRNA derived from 
thyroid hormone target genes in JNK1 deficient mice. Indeed, 
enhanced energy expenditure in nervous system JNK1 defi-
cient mice was due to increased thyroid hormone levels and 
their action [39]. Thus, these results indicate that the hypotha-
lamic-pituitary-thyroid axis is an important target of metabol-
ic regulation by nervous system JNK1. Taken together, all of 
these studies clearly demonstrate that there are cell-autono-
mous effects of JNK1 in adipose tissue, liver, skeletal muscle, 
and brain (Fig. 1). These differential and multifaceted effects 
of JNK1 must be carefully considered in the design of novel 
JNK1-related therapeutic interventions in the treatment of in-
sulin resistance.
MOLECULAR SCAFFOLD KSR2 REGULATES 
ENERGY BALANCE AND GLUCOSE 
METABOLISM
A molecular scaffold, kinase suppressor of Ras 2 (KSR2) is a 
critical regulator of energy balance and glucose homeostasis 
[40]. In both cell culture and animal models, KSR2 deficiency 
results in impaired energy expenditure, reduced glucose and 
lipid metabolism, obesity, and insulin resistance [40]. The un-
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Fig. 1.  cJun NH2-terminal kinase 1 (JNK1) regulates energy balance and glucose and lipid homeostasis via cell-autonomous 
manner. Based on the findings from mice with JNK1 deficiency selectively in adipose tissue, liver, skeletal muscle, or nervous 
system: 1) adipose tissue JNK1 promotes interleukin-6 (IL-6) secretion which causes hepatic insulin resistance in obesity, 2) liver 
JNK1 reduces lipid metabolism and insulin clearance thereby preventing hepatic steatosis and insulin resistance, 3) skeletal mus-
cle JNK1 mediates insulin resistance, adipose tissue inflammation, and suppresses muscle lipoprotein lipase thereby altering cir-
culating triglyceride levels, and 4) nervous system JNK1 mediates the negative feedback regulation of hypothalamic-pituitary-
thyroid axis and promotes negative energy balance by increasing food intake and reducing energy expenditure.141
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is an important sensor of cell’s nutritional status and master reg-
ulator of systemic energy balance [41]. In response to cellular 
stress associated with rising AMP or falling ATP, AMPK is ac-
tivated and increases glucose and lipid metabolism [42]. KSR2 
is shown to directly interact with AMPKa1 subunit and pro-
motes phosphorylation of AMPK on Thr
172, an essential step 
in AMPK signaling. The end result is inhibitory phosphoryla-
tion of ACC, a rate-limiting step in the conversion of acetyl-
CoA to malonyl CoA, and low malonyl CoA level relieves its 
inhibition of carnitine:palmitoyl-CoA transferase-1 (CPT1), a 
rate-controlling step in mitochondrial fatty acid oxidation [43, 
44]. AMPK also increases glucose transport and glycogen me-
tabolism to further restore cellular energy needs [45]. Consis-
tent with this, KSR2 deficient mice showed impaired energy 
expenditure and became obese. KSR2 deficient mice also de-
veloped insulin resistance in multiple organs including skeletal 
muscle, liver, and adipose tissue, which may be due to cell-au-
tonomous effects of KSR2 on glucose and lipid metabolism 
and obesity [40].
  As a master regulator of cellular metabolism, AMPK acts on 
multiple organs including skeletal muscle, adipose tissue, liver, 
heart and brain, and exerts diverse effects to maintain energy 
homeostasis [41]. Alterations in metabolism and energy ex-
penditure are hallmark features of obesity and type 2 diabetes, 
and therapeutic activator of AMPK is actively investigated to 
treat metabolic disease and its complications [46,47]. Thus, the 
current findings on KSR2 regulation of AMPK unveil an excit-


















Fig. 2.  Kinase suppressor of Ras 2 (KSR2) regulates obesity and insulin resistance by activating AMP-activated protein kinase 
(AMPK). KSR2 regulates lipid metabolism by activating AMPK, which phosphorylates and inactivates acetyl CoA carboxylase 
(ACC), and this leads to reduced malonyl CoA level that relieves its inhibition of carnitine:palmitoyl-CoA transferase-1 (CPT1), 
a rate-controlling step in mitochondrial fatty acid oxidation. As a result, KSR2 increases lipid oxidation and reduces lipid storage 
and obesity. KSR2-mediated AMPK activation also increases glucose metabolism and insulin action.142
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targets (Fig. 2). More importantly, this study unveils novel in-
sights into the role of molecular scaffold in energy homeosta-
sis. In that regard, JNK interacting protein 1 is another scaffold 
protein that regulates stress kinase signaling such as JNK1 and 
is involved in glucose metabolism [13,48]. This is yet another 
evidence that other molecular scaffold proteins in the regula-
tion of insulin resistance remain to be discovered.
ENDOPLASMIC RETICULUM CHAPERONE 
GRP78 REGULATES ENERGY BALANCE AND 
INSULIN RESISTANCE
The endoplasmic reticulum (ER) is a specialized perinuclear 
organelle for the synthesis of secretory and membrane-target-
ed proteins. ER stress results from an imbalance between pro-
tein load and folding capacity that leads to unfolded protein 
response (UPR) [49]. The UPR activates 3 major ER signaling 
pathways: 1) PKR-like endoplasmic reticulum kinase, 2) inosi-
tol requiring-1 (IRE-1), and 3) activating transcription factor 
6 [50]. In obese state, intracellular lipid accumulation activates 
IRE-1 and the stress kinase signaling such as JNK1 [14]. Treat-
ment with chemical chaperones such as 4-phenyl butyric acid 
or tauroursodeoxycholic acid has been shown to attenuate ER 
stress and improve insulin sensitivity in diet-induced obese 
mice [51]. These observations implicate an important role of 
ER homeostasis in obesity and insulin resistance.
  The 78-kDa glucose regulated protein, GRP78, also known 
as BiP (immunoglobulin heavy-chain binding protein) or 
HSPA5, is a key rheostat in regulating ER homeostasis [52]. 
GRP78 regulates ER function via protein folding and assembly, 
targeting misfolded protein for degradation, ER Ca
2+ binding, 
and controlling the activation of transmembrane ER stress sen-
sors [52]. To determine the role of ER stress in obesity, mice 
with heterozygous deletion of Grp78 were recently developed 
and shown to be resistant to diet-induced obesity [53]. Grp78 
deficient mice showed enhanced whole body energy expendi-
ture, and were more insulin sensitive as compared to wild-type 
littermates following HFD [53]. This unexpected finding in 
which Grp78 heterozygosity improves energy balance and in-
sulin sensitivity is due to remarkable activation of adaptive 
UPR, which resulted in improved ER homeostasis in adipose 
tissue [53]. Thus, these findings support the important role of 
ER homeostasis and ER stress in energy balance and the regu-
lation of glucose metabolism.
FUTURE QUESTIONS
If inflammation develops in white adipose tissue, liver, and 
skeletal muscle, what other organs are affected by inflamma-
tion in obesity? Herrero et al. [54] recently showed that brown 
adipose tissue develops macrophage infiltration and inflam-
mation in lipodystrophic mice. A recent study from our group 
found that diet-induced obesity causes macrophage infiltra-
tion in heart, and elevated IL-6 levels suppress AMPK activity 
and myocardial glucose metabolism [55]. It will be important 
to determine what other organs develop inflammation, and 
how they may contribute to insulin resistance in obesity.
  If inflammatory cytokines such as IL-6 and TNF-a mediate 
insulin resistance, are there cytokines that oppose the action 
of IL-6 and TNF-a and positively regulate insulin sensitivity? 
In that regard, IL-10 is a potent inhibitor of the pro-inflamma-
tory cytokines and chemokines [56]. Plasma IL-10 levels are 
positively related to insulin sensitivity in healthy subjects, and 
IL-10 levels are reduced in obese, diabetic subjects [57,58]. A 
recent report from Lumeng et al. [59] demonstrated that adi-
pose tissue macrophages from lean animals express polariza-
tion toward an alternatively activated state, and this was asso-
ciated with increased expression of IL-10. This study further 
showed that IL-10 increases glucose uptake and protects against 
TNF-a mediated insulin resistance in isolated adipocytes [59]. 
Moreover, our recent study found that elevation of IL-10 levels 
by chronic IL-10 treatment or transgenic overexpression of IL-
10 improves insulin sensitivity in skeletal muscle following 
HFD [32]. It will be important to further understand the met-
abolic role of IL-10 and discover other cytokines that may reg-
ulate insulin resistance.
CONCLUSION
It is not presumptuous to state that diabetes is an inflammato-
ry disease. At the cellular level, it involves a complex network 
of stress kinase signaling, molecular scaffolds, and ER chaper-
ones. At the systemic level, cytokines play a major role in 
cross-talk between organs. Diabetes is neither an energy defi-
cient nor energy surplus state. Instead, it is a state of energy 
imbalance. In the past decade, we have acquired a greater un-
derstanding of molecular events and signaling pathways to 
link inflammation and insulin resistance. They are new excit-
ing ideas for an age-old question.143
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